Global Prostate Cancer Market
Global Prostate Cancer Market

Prostate Cancer Comprehensive Study by Type (Hormone sensitive prostate cancer, Hormone refractory prostate cancer), Application (Chemotherapy, Hormonal Therapy, Targeted Therapy, Immunotherapy), Therapy (Chemotherapy (Cytotoxic drugs), Hormonal Therapy (Anti-Androgens) Players and Region - Global Market Outlook to 2025

Prostate Cancer Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 210 Pages 183 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Prostate Cancer Market?

Prostate Cancer is type of cancer mainly found in male’s Prostate glands. It is minor walnut-shaped gland in men that produces the seminal fluid that sustains and carriages sperm. Prostate cancer is start when cells are begin to grow out of control in the prostate gland. There are main two type of prostate cancer hormone sensitive prostate cancer and hormone refractory prostate cancer. Other type of prostate cancer are sarcomas, small cell carcinomas, neuroendocrine tumors and transitional cell carcinomas. Burning or pain during urination. Rising trouble urinating, difficulty in starting and stopping while urinating and frequent urges to urinate at night are some symptoms of the prostate cancer.

The market study is being classified by Type (Hormone sensitive prostate cancer and Hormone refractory prostate cancer), by Application (Chemotherapy, Hormonal Therapy, Targeted Therapy and Immunotherapy) and major geographies with country level break-up.

Astellas, Inc. (Japan), AstraZeneca plc. (United Kingdom), Johnson & Johnson (United States), Sanofi S.A (France), Bristol Myers Squibb (BMS) (United States), Bayer AG (Germany), Abbott (United States), BioMark Diagnostics Inc. (Canada), Sanofi (France) and Ipsen (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are TOLMAR Pharmaceuticals Inc. (United States) and Indevus Pharmaceuticals Inc. (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Prostate Cancer market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Prostate Cancer market by Type, Application and Region.

On the basis of geography, the market of Prostate Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Availability of Enhanced Diagnosis Centers in Emerging Countries
  • Rising Awareness about the Treatment

Market Trend
  • Growing Dependency on Advanced Drugs
  • Adoption of Advance Oncology Diagnostics Technology

Restraints
  • High Prices
  • Lengthy Treatment Periods

Opportunities
  • Rising Treatment Facility in Rural Regions of Developing Countries


Market Leaders and some development strategies
On 23rd January 2018, Astellas Pharma Inc. has acquired Mitobridge, Inc. (a biotechnology company, discovers and develops novel small molecule therapeutics that improve mitochondrial functions). The deal was established for 225 million dollar.
On 29th October 2018, Astellas Pharma Inc. has announced that they get approval from European Commission (EC) for a new indication for XTANDI. This XTANDI (enzalutamide) is used for treatment of adult men with high-risk, non-metastatic, castration-resistant prostate cancer.


Key Target Audience
Prostate Cancer Treatment Provider, Health care Industry, Pharmaceutical Industry, Medical Research Institutes, Government and Private Research Institutes and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Hormone sensitive prostate cancer
  • Hormone refractory prostate cancer
By Application
  • Chemotherapy
  • Hormonal Therapy
  • Targeted Therapy
  • Immunotherapy
By Therapy
  • Chemotherapy (Cytotoxic drugs)
  • Hormonal Therapy (Anti-Androgens

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Availability of Enhanced Diagnosis Centers in Emerging Countries
      • 3.2.2. Rising Awareness about the Treatment
    • 3.3. Market Trends
      • 3.3.1. Growing Dependency on Advanced Drugs
      • 3.3.2. Adoption of Advance Oncology Diagnostics Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prostate Cancer, by Type, Application, Therapy and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Prostate Cancer (Value)
      • 5.2.1. Global Prostate Cancer by: Type (Value)
        • 5.2.1.1. Hormone sensitive prostate cancer
        • 5.2.1.2. Hormone refractory prostate cancer
      • 5.2.2. Global Prostate Cancer by: Application (Value)
        • 5.2.2.1. Chemotherapy
        • 5.2.2.2. Hormonal Therapy
        • 5.2.2.3. Targeted Therapy
        • 5.2.2.4. Immunotherapy
      • 5.2.3. Global Prostate Cancer by: Therapy (Value)
        • 5.2.3.1. Chemotherapy (Cytotoxic drugs)
        • 5.2.3.2. Hormonal Therapy (Anti-Androgens
      • 5.2.4. Global Prostate Cancer Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Prostate Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas, Inc. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi S.A (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol Myers Squibb (BMS) (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bayer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BioMark Diagnostics Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ipsen (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Prostate Cancer Sale, by Type, Application, Therapy and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Prostate Cancer (Value)
      • 7.2.1. Global Prostate Cancer by: Type (Value)
        • 7.2.1.1. Hormone sensitive prostate cancer
        • 7.2.1.2. Hormone refractory prostate cancer
      • 7.2.2. Global Prostate Cancer by: Application (Value)
        • 7.2.2.1. Chemotherapy
        • 7.2.2.2. Hormonal Therapy
        • 7.2.2.3. Targeted Therapy
        • 7.2.2.4. Immunotherapy
      • 7.2.3. Global Prostate Cancer by: Therapy (Value)
        • 7.2.3.1. Chemotherapy (Cytotoxic drugs)
        • 7.2.3.2. Hormonal Therapy (Anti-Androgens
      • 7.2.4. Global Prostate Cancer Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prostate Cancer: by Type(USD Million)
  • Table 2. Prostate Cancer Hormone sensitive prostate cancer , by Region USD Million (2014-2019)
  • Table 3. Prostate Cancer Hormone refractory prostate cancer , by Region USD Million (2014-2019)
  • Table 4. Prostate Cancer: by Application(USD Million)
  • Table 5. Prostate Cancer Chemotherapy , by Region USD Million (2014-2019)
  • Table 6. Prostate Cancer Hormonal Therapy , by Region USD Million (2014-2019)
  • Table 7. Prostate Cancer Targeted Therapy , by Region USD Million (2014-2019)
  • Table 8. Prostate Cancer Immunotherapy , by Region USD Million (2014-2019)
  • Table 9. Prostate Cancer: by Therapy(USD Million)
  • Table 10. Prostate Cancer Chemotherapy (Cytotoxic drugs) , by Region USD Million (2014-2019)
  • Table 11. Prostate Cancer Hormonal Therapy (Anti-Androgens , by Region USD Million (2014-2019)
  • Table 12. South America Prostate Cancer, by Country USD Million (2014-2019)
  • Table 13. South America Prostate Cancer, by Type USD Million (2014-2019)
  • Table 14. South America Prostate Cancer, by Application USD Million (2014-2019)
  • Table 15. South America Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 16. Brazil Prostate Cancer, by Type USD Million (2014-2019)
  • Table 17. Brazil Prostate Cancer, by Application USD Million (2014-2019)
  • Table 18. Brazil Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 19. Argentina Prostate Cancer, by Type USD Million (2014-2019)
  • Table 20. Argentina Prostate Cancer, by Application USD Million (2014-2019)
  • Table 21. Argentina Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 22. Rest of South America Prostate Cancer, by Type USD Million (2014-2019)
  • Table 23. Rest of South America Prostate Cancer, by Application USD Million (2014-2019)
  • Table 24. Rest of South America Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 25. Asia Pacific Prostate Cancer, by Country USD Million (2014-2019)
  • Table 26. Asia Pacific Prostate Cancer, by Type USD Million (2014-2019)
  • Table 27. Asia Pacific Prostate Cancer, by Application USD Million (2014-2019)
  • Table 28. Asia Pacific Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 29. China Prostate Cancer, by Type USD Million (2014-2019)
  • Table 30. China Prostate Cancer, by Application USD Million (2014-2019)
  • Table 31. China Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 32. Japan Prostate Cancer, by Type USD Million (2014-2019)
  • Table 33. Japan Prostate Cancer, by Application USD Million (2014-2019)
  • Table 34. Japan Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 35. India Prostate Cancer, by Type USD Million (2014-2019)
  • Table 36. India Prostate Cancer, by Application USD Million (2014-2019)
  • Table 37. India Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 38. South Korea Prostate Cancer, by Type USD Million (2014-2019)
  • Table 39. South Korea Prostate Cancer, by Application USD Million (2014-2019)
  • Table 40. South Korea Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 41. Taiwan Prostate Cancer, by Type USD Million (2014-2019)
  • Table 42. Taiwan Prostate Cancer, by Application USD Million (2014-2019)
  • Table 43. Taiwan Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 44. Australia Prostate Cancer, by Type USD Million (2014-2019)
  • Table 45. Australia Prostate Cancer, by Application USD Million (2014-2019)
  • Table 46. Australia Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 47. Rest of Asia-Pacific Prostate Cancer, by Type USD Million (2014-2019)
  • Table 48. Rest of Asia-Pacific Prostate Cancer, by Application USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 50. Europe Prostate Cancer, by Country USD Million (2014-2019)
  • Table 51. Europe Prostate Cancer, by Type USD Million (2014-2019)
  • Table 52. Europe Prostate Cancer, by Application USD Million (2014-2019)
  • Table 53. Europe Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 54. Germany Prostate Cancer, by Type USD Million (2014-2019)
  • Table 55. Germany Prostate Cancer, by Application USD Million (2014-2019)
  • Table 56. Germany Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 57. France Prostate Cancer, by Type USD Million (2014-2019)
  • Table 58. France Prostate Cancer, by Application USD Million (2014-2019)
  • Table 59. France Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 60. Italy Prostate Cancer, by Type USD Million (2014-2019)
  • Table 61. Italy Prostate Cancer, by Application USD Million (2014-2019)
  • Table 62. Italy Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 63. United Kingdom Prostate Cancer, by Type USD Million (2014-2019)
  • Table 64. United Kingdom Prostate Cancer, by Application USD Million (2014-2019)
  • Table 65. United Kingdom Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 66. Netherlands Prostate Cancer, by Type USD Million (2014-2019)
  • Table 67. Netherlands Prostate Cancer, by Application USD Million (2014-2019)
  • Table 68. Netherlands Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 69. Rest of Europe Prostate Cancer, by Type USD Million (2014-2019)
  • Table 70. Rest of Europe Prostate Cancer, by Application USD Million (2014-2019)
  • Table 71. Rest of Europe Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 72. MEA Prostate Cancer, by Country USD Million (2014-2019)
  • Table 73. MEA Prostate Cancer, by Type USD Million (2014-2019)
  • Table 74. MEA Prostate Cancer, by Application USD Million (2014-2019)
  • Table 75. MEA Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 76. Middle East Prostate Cancer, by Type USD Million (2014-2019)
  • Table 77. Middle East Prostate Cancer, by Application USD Million (2014-2019)
  • Table 78. Middle East Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 79. Africa Prostate Cancer, by Type USD Million (2014-2019)
  • Table 80. Africa Prostate Cancer, by Application USD Million (2014-2019)
  • Table 81. Africa Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 82. North America Prostate Cancer, by Country USD Million (2014-2019)
  • Table 83. North America Prostate Cancer, by Type USD Million (2014-2019)
  • Table 84. North America Prostate Cancer, by Application USD Million (2014-2019)
  • Table 85. North America Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 86. United States Prostate Cancer, by Type USD Million (2014-2019)
  • Table 87. United States Prostate Cancer, by Application USD Million (2014-2019)
  • Table 88. United States Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 89. Canada Prostate Cancer, by Type USD Million (2014-2019)
  • Table 90. Canada Prostate Cancer, by Application USD Million (2014-2019)
  • Table 91. Canada Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 92. Mexico Prostate Cancer, by Type USD Million (2014-2019)
  • Table 93. Mexico Prostate Cancer, by Application USD Million (2014-2019)
  • Table 94. Mexico Prostate Cancer, by Therapy USD Million (2014-2019)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Prostate Cancer: by Type(USD Million)
  • Table 106. Prostate Cancer Hormone sensitive prostate cancer , by Region USD Million (2020-2025)
  • Table 107. Prostate Cancer Hormone refractory prostate cancer , by Region USD Million (2020-2025)
  • Table 108. Prostate Cancer: by Application(USD Million)
  • Table 109. Prostate Cancer Chemotherapy , by Region USD Million (2020-2025)
  • Table 110. Prostate Cancer Hormonal Therapy , by Region USD Million (2020-2025)
  • Table 111. Prostate Cancer Targeted Therapy , by Region USD Million (2020-2025)
  • Table 112. Prostate Cancer Immunotherapy , by Region USD Million (2020-2025)
  • Table 113. Prostate Cancer: by Therapy(USD Million)
  • Table 114. Prostate Cancer Chemotherapy (Cytotoxic drugs) , by Region USD Million (2020-2025)
  • Table 115. Prostate Cancer Hormonal Therapy (Anti-Androgens , by Region USD Million (2020-2025)
  • Table 116. South America Prostate Cancer, by Country USD Million (2020-2025)
  • Table 117. South America Prostate Cancer, by Type USD Million (2020-2025)
  • Table 118. South America Prostate Cancer, by Application USD Million (2020-2025)
  • Table 119. South America Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 120. Brazil Prostate Cancer, by Type USD Million (2020-2025)
  • Table 121. Brazil Prostate Cancer, by Application USD Million (2020-2025)
  • Table 122. Brazil Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 123. Argentina Prostate Cancer, by Type USD Million (2020-2025)
  • Table 124. Argentina Prostate Cancer, by Application USD Million (2020-2025)
  • Table 125. Argentina Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 126. Rest of South America Prostate Cancer, by Type USD Million (2020-2025)
  • Table 127. Rest of South America Prostate Cancer, by Application USD Million (2020-2025)
  • Table 128. Rest of South America Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 129. Asia Pacific Prostate Cancer, by Country USD Million (2020-2025)
  • Table 130. Asia Pacific Prostate Cancer, by Type USD Million (2020-2025)
  • Table 131. Asia Pacific Prostate Cancer, by Application USD Million (2020-2025)
  • Table 132. Asia Pacific Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 133. China Prostate Cancer, by Type USD Million (2020-2025)
  • Table 134. China Prostate Cancer, by Application USD Million (2020-2025)
  • Table 135. China Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 136. Japan Prostate Cancer, by Type USD Million (2020-2025)
  • Table 137. Japan Prostate Cancer, by Application USD Million (2020-2025)
  • Table 138. Japan Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 139. India Prostate Cancer, by Type USD Million (2020-2025)
  • Table 140. India Prostate Cancer, by Application USD Million (2020-2025)
  • Table 141. India Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 142. South Korea Prostate Cancer, by Type USD Million (2020-2025)
  • Table 143. South Korea Prostate Cancer, by Application USD Million (2020-2025)
  • Table 144. South Korea Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 145. Taiwan Prostate Cancer, by Type USD Million (2020-2025)
  • Table 146. Taiwan Prostate Cancer, by Application USD Million (2020-2025)
  • Table 147. Taiwan Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 148. Australia Prostate Cancer, by Type USD Million (2020-2025)
  • Table 149. Australia Prostate Cancer, by Application USD Million (2020-2025)
  • Table 150. Australia Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 151. Rest of Asia-Pacific Prostate Cancer, by Type USD Million (2020-2025)
  • Table 152. Rest of Asia-Pacific Prostate Cancer, by Application USD Million (2020-2025)
  • Table 153. Rest of Asia-Pacific Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 154. Europe Prostate Cancer, by Country USD Million (2020-2025)
  • Table 155. Europe Prostate Cancer, by Type USD Million (2020-2025)
  • Table 156. Europe Prostate Cancer, by Application USD Million (2020-2025)
  • Table 157. Europe Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 158. Germany Prostate Cancer, by Type USD Million (2020-2025)
  • Table 159. Germany Prostate Cancer, by Application USD Million (2020-2025)
  • Table 160. Germany Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 161. France Prostate Cancer, by Type USD Million (2020-2025)
  • Table 162. France Prostate Cancer, by Application USD Million (2020-2025)
  • Table 163. France Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 164. Italy Prostate Cancer, by Type USD Million (2020-2025)
  • Table 165. Italy Prostate Cancer, by Application USD Million (2020-2025)
  • Table 166. Italy Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 167. United Kingdom Prostate Cancer, by Type USD Million (2020-2025)
  • Table 168. United Kingdom Prostate Cancer, by Application USD Million (2020-2025)
  • Table 169. United Kingdom Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 170. Netherlands Prostate Cancer, by Type USD Million (2020-2025)
  • Table 171. Netherlands Prostate Cancer, by Application USD Million (2020-2025)
  • Table 172. Netherlands Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 173. Rest of Europe Prostate Cancer, by Type USD Million (2020-2025)
  • Table 174. Rest of Europe Prostate Cancer, by Application USD Million (2020-2025)
  • Table 175. Rest of Europe Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 176. MEA Prostate Cancer, by Country USD Million (2020-2025)
  • Table 177. MEA Prostate Cancer, by Type USD Million (2020-2025)
  • Table 178. MEA Prostate Cancer, by Application USD Million (2020-2025)
  • Table 179. MEA Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 180. Middle East Prostate Cancer, by Type USD Million (2020-2025)
  • Table 181. Middle East Prostate Cancer, by Application USD Million (2020-2025)
  • Table 182. Middle East Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 183. Africa Prostate Cancer, by Type USD Million (2020-2025)
  • Table 184. Africa Prostate Cancer, by Application USD Million (2020-2025)
  • Table 185. Africa Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 186. North America Prostate Cancer, by Country USD Million (2020-2025)
  • Table 187. North America Prostate Cancer, by Type USD Million (2020-2025)
  • Table 188. North America Prostate Cancer, by Application USD Million (2020-2025)
  • Table 189. North America Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 190. United States Prostate Cancer, by Type USD Million (2020-2025)
  • Table 191. United States Prostate Cancer, by Application USD Million (2020-2025)
  • Table 192. United States Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 193. Canada Prostate Cancer, by Type USD Million (2020-2025)
  • Table 194. Canada Prostate Cancer, by Application USD Million (2020-2025)
  • Table 195. Canada Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 196. Mexico Prostate Cancer, by Type USD Million (2020-2025)
  • Table 197. Mexico Prostate Cancer, by Application USD Million (2020-2025)
  • Table 198. Mexico Prostate Cancer, by Therapy USD Million (2020-2025)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prostate Cancer: by Type USD Million (2014-2019)
  • Figure 5. Global Prostate Cancer: by Application USD Million (2014-2019)
  • Figure 6. Global Prostate Cancer: by Therapy USD Million (2014-2019)
  • Figure 7. South America Prostate Cancer Share (%), by Country
  • Figure 8. Asia Pacific Prostate Cancer Share (%), by Country
  • Figure 9. Europe Prostate Cancer Share (%), by Country
  • Figure 10. MEA Prostate Cancer Share (%), by Country
  • Figure 11. North America Prostate Cancer Share (%), by Country
  • Figure 12. Global Prostate Cancer share by Players 2019 (%)
  • Figure 13. Global Prostate Cancer share by Players (Top 3) 2019(%)
  • Figure 14. Global Prostate Cancer share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Astellas, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Astellas, Inc. (Japan) Revenue: by Geography 2019
  • Figure 18. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2019
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2019
  • Figure 22. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi S.A (France) Revenue: by Geography 2019
  • Figure 24. Bristol Myers Squibb (BMS) (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bristol Myers Squibb (BMS) (United States) Revenue: by Geography 2019
  • Figure 26. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 28. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 29. Abbott (United States) Revenue: by Geography 2019
  • Figure 30. BioMark Diagnostics Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 31. BioMark Diagnostics Inc. (Canada) Revenue: by Geography 2019
  • Figure 32. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi (France) Revenue: by Geography 2019
  • Figure 34. Ipsen (France) Revenue, Net Income and Gross profit
  • Figure 35. Ipsen (France) Revenue: by Geography 2019
  • Figure 36. Global Prostate Cancer: by Type USD Million (2020-2025)
  • Figure 37. Global Prostate Cancer: by Application USD Million (2020-2025)
  • Figure 38. Global Prostate Cancer: by Therapy USD Million (2020-2025)
  • Figure 39. South America Prostate Cancer Share (%), by Country
  • Figure 40. Asia Pacific Prostate Cancer Share (%), by Country
  • Figure 41. Europe Prostate Cancer Share (%), by Country
  • Figure 42. MEA Prostate Cancer Share (%), by Country
  • Figure 43. North America Prostate Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Astellas, Inc. (Japan)
  • AstraZeneca plc. (United Kingdom)
  • Johnson & Johnson (United States)
  • Sanofi S.A (France)
  • Bristol Myers Squibb (BMS) (United States)
  • Bayer AG (Germany)
  • Abbott (United States)
  • BioMark Diagnostics Inc. (Canada)
  • Sanofi (France)
  • Ipsen (France)
Additional players considered in the study are as follows:
TOLMAR Pharmaceuticals Inc. (United States) , Indevus Pharmaceuticals Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation